InvestorsHub Logo
Followers 86
Posts 1770
Boards Moderated 0
Alias Born 09/03/2009

Re: None

Wednesday, 11/01/2017 1:15:59 PM

Wednesday, November 01, 2017 1:15:59 PM

Post# of 8449
Today's news is superb. If you look at the trials of NT-219 in conjunction with Gemcitabine (Gemzar) on page 25 of KITOV's June 2017 presentation, it shows the effectiveness of the combo to counter the acquired tumor resistance to Gemcitabine.

It is nothing short of amazing. Granted this is a human tumor implanted in a mouse, so not yet all human, but the effectiveness, if confirmed in human trials, would be a game changer.

Millstone